» Articles » PMID: 37602239

Acute Necrotizing Encephalopathy in Children with COVID-19: a Retrospective Study of 12 Cases

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Aug 21
PMID 37602239
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute necrotizing encephalopathy (ANE) is a devastating neurologic condition that can arise following a variety of systemic infections, including influenza and SARS-Cov-2. The clinical features of COVID-19-associated ANE in pediatric patients based on multi-case data have not yet been described and remain obscure. We reviewed 12 pediatric patients to better describe the clinical features of ANE with COVID-19.

Methods: We retrospectively collected and summarized the clinical features of ANE in children with COVID-19. Clinical data were collected from 12 children, including their general status, clinical symptoms, laboratory tests, and neuroimaging features.

Results: Among the subjects, 10 were over 5 years old and they accounted for 83.33%. A large percentage of those affected (66.67%) were females. The major manifestations included fever (100%), impaired consciousness (100%), and convulsions (75%). We determined that increased interleukin (IL)-6 and IL-10, and tumor necrosis factor-α and interferon gamma were not predictive of severe ANE and mortality in children with COVID-19 in this study. All children presented with abnormal neuroimaging with multiple and symmetrically distributed lesions, involving the thalamus, basal ganglia, cerebellum, and brain hemispheres. Eight of the 12 children died, resulting in a mortality rate of 66.67%, and 75% of these children were females. Importantly, we found the timely administration of mannitol after an acute onset of convulsions or disturbance of consciousness may be decreased the high mortality induced by ANE children with COVID-19.

Conclusion: COVID-19 associated with ANE in children is characterized by sudden symptom onset, rapid disease progression, and high mortality.

Citing Articles

Predictive value of ANE-SS combined with ferritin and DIC scores for mortality Risk in children with acute necrotizing encephalopathy.

Li F, Li K, Wang Q, Qian S, Fan C Transl Pediatr. 2025; 14(1):42-51.

PMID: 39944865 PMC: 11811582. DOI: 10.21037/tp-24-416.


Severe central nervous system injury in 9 children with COVID-19.

Zhang P, Xin M, Bai Y, Ren X, Li N BMC Pediatr. 2025; 25(1):63.

PMID: 39871225 PMC: 11771022. DOI: 10.1186/s12887-025-05436-8.


Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2.

Nicoliche T, Bartolomeo C, Lemes R, Pereira G, Nunes T, Oliveira R Sci Rep. 2024; 14(1):10696.

PMID: 38730068 PMC: 11087556. DOI: 10.1038/s41598-024-61662-7.


Quadriplegia, Dysphagia and Ataxia Manifested in a Child With COVID-19 Related Acute Necrotizing Encephalopathy: A Case Report.

Ku Y, Joa K, Kim M, Kim C, Jung H Brain Neurorehabil. 2024; 17(1):e2.

PMID: 38585028 PMC: 10990845. DOI: 10.12786/bn.2024.17.e2.


Clinical characteristics and outcomes of COVID-19-associated encephalopathy in children.

Li L, Liao H, Kuang X, Jin K J Neurovirol. 2024; 30(2):187-196.

PMID: 38570476 DOI: 10.1007/s13365-024-01202-1.


References
1.
Saraiva M, OGarra A . The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010; 10(3):170-81. DOI: 10.1038/nri2711. View

2.
Gadani S, Cohen A . Acute Necrotizing Encephalitis as an Early Manifestation of COVID-19. Cureus. 2022; 14(8):e27928. PMC: 9464457. DOI: 10.7759/cureus.27928. View

3.
Forest C, Laudisi M, Malaventura C, Tugnoli V, Pellino G, Marangoni E . Pediatric recurrent acute necrotizing encephalomyelitis, RANBP2 genotype and Sars-CoV-2 infection: Diagnosis, pathogenesis and targeted treatments from a case study. Eur J Paediatr Neurol. 2023; 42:117-121. DOI: 10.1016/j.ejpn.2022.12.010. View

4.
Pedersen S, Ho Y . SARS-CoV-2: a storm is raging. J Clin Invest. 2020; 130(5):2202-2205. PMC: 7190904. DOI: 10.1172/JCI137647. View

5.
Venkatesan A, Murphy O . Viral Encephalitis. Neurol Clin. 2018; 36(4):705-724. DOI: 10.1016/j.ncl.2018.07.001. View